XML 77 R56.htm IDEA: XBRL DOCUMENT v3.22.4
Collaboration Agreements,License Agreement and Revenues - Drug Product Revenue - Additional Information (Detail) - USD ($)
3 Months Ended 12 Months Ended
Dec. 31, 2022
Jun. 30, 2022
Mar. 31, 2022
Mar. 31, 2021
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Drug product revenue recognized         $ 140,734,000 $ 235,309,000 $ 176,319,000
Deferred Revenue $ 12,739,000       12,739,000 15,857,000  
Prepaid Supplies 17,488,000       17,488,000 66,909,000  
Astra Zeneca Agreements [Member]              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Recognized as Revenue         71,167,000    
Drug Product Revenue [Member]              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Drug product revenue recognized         11,086,000 962,000 8,906,000
Drug Product Revenue [Member] | API Shipment [Member]              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Drug product revenue recognized         (4,000,000.0) 2,100,000  
Drug Product Revenue [Member] | Astellas Agreement [Member]              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Drug product revenue recognized         11,100,000    
Drug Product Revenue [Member] | Japan [Member]              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Drug product revenue recognized 8,400,000   $ 9,800,000   8,200,000    
Accrued liabilities 6,500,000       6,500,000    
Drug Product Revenue [Member] | Japan [Member] | API Shipment [Member]              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Drug product revenue recognized         8,700,000    
Drug Product Revenue [Member] | Japan [Member] | Astellas Agreement [Member]              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Drug product revenue recognized         9,480,000 2,056,000 4,281,000
Drug Product Revenue [Member] | Europe [Member] | Astellas Agreement [Member]              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Drug product revenue recognized         1,606,000 1,130,000 0
Drug Product Revenue [Member] | Europe [Member] | Astellas Europe Agreement [Member]              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Burdened manufacturing costs   $ 1,000,000.0   $ 1,000,000.0      
Bulk Drug Product | Astellas Europe Agreement [Member]              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Deferred Revenue           8,300,000  
Bulk Drug Product | Astra Zeneca Agreements [Member]              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Drug product revenue recognized         11,200,000 11,200,000  
Accrued liabilities 11,200,000       11,200,000 2,200,000 4,600,000
Bulk Drug Product | Europe [Member] | Astellas Europe Agreement [Member]              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Drug product revenue recognized         57,400,000    
Deferred Revenue 23,200,000       23,200,000 11,800,000 $ 6,000,000.0
Prepaid Supplies           49,800,000  
Billed Contracts Receivable 49,200,000       49,200,000    
Accrued liabilities $ 57,400,000       57,400,000    
Bulk Drug Product | Europe [Member] | Astellas Europe Agreement [Member] | Royalty Revenue [Member]              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Recognized as Revenue         $ 600 $ 200